Peripheral T-Cell Lymphoma

Current Location

54 Peripheral T-Cell Lymphoma Trials Near You

Power is an online platform that helps thousands of Peripheral T-Cell Lymphoma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

DR-01 for Leukemia and Lymphoma

Columbus, Ohio
This trial is testing a new drug called DR-01 to see if it is safe and effective for adults with specific blood cancers. The study will check if the drug can safely reach and affect cancer cells to stop their growth.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

69 Participants Needed

Chemoimmunotherapy + Stem Cell Transplant for NK T-cell Lymphoma/Leukemia

Columbus, Ohio
Patients are in 2 cohorts: Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX) (Cycles 1, 2, 4, 6) and brentuximab vedotin (BV) (Cycles 3, 5) to cyclophosphamide, doxorubicin, and prednisone in children, adolescent, and young adults with advanced peripheral T-cell lymphoma (non-anaplastic large cell lymphoma or non-NK lymphoma/leukemia) . Both groups proceed to allogeneic stem cell transplant with disease response.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:1 - 31

40 Participants Needed

Letermovir for Preventing Infection in Blood Cancer Patients

Columbus, Ohio
This trial studies how well letermovir prevents CMV reactivation in patients with blood cancers treated with alemtuzumab. Letermovir works by stopping the virus from making more copies of itself. The goal is to see if it can effectively prevent CMV infections in these patients. Letermovir is an antiviral drug approved for preventing CMV infections, primarily studied for a few months after treatment.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

6 Participants Needed

Romidepsin Combination Therapy for Lymphoma

Columbus, Ohio
The goal of this clinical research study is to learn if giving romidepsin before and after a stem cell transplant in combination with fludarabine and busulfan can help to control leukemia or lymphoma. Researchers also want to learn the highest tolerable dose of romidepsin that can be given with this combination. The safety of this combination and the safety of giving romidepsin after a stem cell transplant will also be studied. This is an investigational study. Romidepsin is FDA approved and commercially available for the treatment of CTCL in patients who have received at least 1 systemic (affecting the whole body) therapy before. Busulfan and fludarabine are FDA approved and commercially available for use with a stem cell transplant. The use of the combination of romidepsin, busulfan, and fludarabine to treat the type of leukemia or lymphoma you have is considered investigational. Up to 30 participants will be enrolled in this study. All will take part at MD Anderson.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

23 Participants Needed

Duvelisib/CC-486 + Chemotherapy for Lymphoma

Columbus, Ohio
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

170 Participants Needed

KT-333 for Lymphoma and Cancer

Columbus, Ohio
This trial is testing a new drug called KT-333 in adults with certain cancers that haven't responded to other treatments. The goal is to see if the drug is safe and how it works in the body.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

120 Participants Needed

Brentuximab + Chemotherapy for T-Cell Lymphoma

Columbus, Ohio
This phase II trial studies the side effects and how well brentuximab vedotin and combination chemotherapy work in treating patients with CD30-positive peripheral T-cell lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, etoposide, and prednisone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and combination chemotherapy may work better in treating patients with CD30-positive peripheral T-cell lymphoma.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

48 Participants Needed

DS-3201b for Lymphoma

Columbus, Ohio
DS-3201b is an experimental drug that is being investigated in clinical research. Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to current treatment This study has three parts. The Dose Escalation part is designed is to find the safe dose of DS-3201b that adults with advanced NHL can tolerate. The Dose Expansion phase will determine how effective DS-3201b is for rare types of NH and collect additional safety data. Last, the Drug-Drug Interaction (DDI) Cohort (US Only) will evaluate the effect of DS-3201b on the pharmacokinetics (PK) of midazolam and digoxin when co-administered to patients with NHL
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

100 Participants Needed

Nanatinostat + Valganciclovir for EBV-Positive Lymphoma

Columbus, Ohio
This trial tests a combination of nanatinostat and valganciclovir in patients with relapsed or refractory EBV-positive lymphomas. Nanatinostat helps the virus produce proteins that activate valganciclovir to kill cancer cells. The goal is to improve outcomes for these patients. Nanatinostat has shown promise in making EBV-positive lymphoma cells more responsive to antiviral agents.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

140 Participants Needed

CPI-818 for T-Cell Lymphoma

Columbus, Ohio
This trial is testing a new pill called CPI-818 for patients with T-cell lymphoma that hasn't responded to other treatments. The pill works by blocking a protein that helps cancer cells grow.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

151 Participants Needed

Anti-ICOS Monoclonal Antibody for Peripheral T-cell Lymphoma

Columbus, Ohio
This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

21 Participants Needed

Brentuximab Vedotin + CHP for T-Cell Lymphoma

Fairfield, Ohio
This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side effects occur when brentuximab vedotin and CHP are used together. A side effect is anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat certain types of PTCL.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

82 Participants Needed

AFM13 + AB-101 for Lymphoma

Cleveland, Ohio
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

154 Participants Needed

ONO-4685 for Lymphoma

Cleveland, Ohio
This trial will test a new drug called ONO-4685 in patients whose T cell Lymphoma has come back or did not respond to previous treatments. Researchers aim to see if the drug is safe, how it moves through the body, and if it helps reduce the cancer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

217 Participants Needed

ARV-393 for Non-Hodgkin's Lymphoma

Cleveland, Ohio
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

112 Participants Needed

Brentuximab Vedotin for T-Cell Lymphoma

Cleveland, Ohio
This study will include patients with mature T-cell lymphoma (MTCL) that has been treated with at least one type of chemotherapy, but is not responding or coming back after the previous treatment. This clinical trial uses a drug called Brentuximab Vedotin. The Food and Drug Administration (FDA) has approved Brentuximab Vedotin for sale in the United States for certain diseases. Brentuximab is still being studied in clinical trials like this one to learn more about what its side effects are and whether or not it is effective in the disease or condition being studied. Brentuximab Vedotin is a type of drug called an antibody drug conjugate (ADC). ADCs usually have 2 parts; a part that targets cancer cells (the antibody) and a cell killing part (the chemotherapy). Antibodies are proteins that are part of your immune system. They can stick to and attack specific targets on cells. The antibody part of Brentuximab Vedotin sticks to a target called CD30. CD30 is an important molecule on some cancer cells (including non Hodgkin lymphoma) and some normal cells of the immune system. The cell killing part of Brentuximab Vedotin is a chemotherapy called monomethyl auristatin E (MMAE). It can kill cells that the antibody part of Brentuximab Vedotin sticks to. Brentuximab Vedotin has also been shown to kill cancer cells with levels of CD30 that cannot be seen by traditional methods. This study is being done to test if the study drug has an effect on Mature T cell Lymphoma with such low levels of a target called CD30 and how your disease respond to the study drug.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

23 Participants Needed

Tolinapant + Decitabine/Cedazuridine for Peripheral T-Cell Lymphoma

Ann Arbor, Michigan
The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

33 Participants Needed

Pembrolizumab + Decitabine + Pralatrexate for T-Cell Lymphoma

Pittsburgh, Pennsylvania
This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

37 Participants Needed

CCS1477 for Blood Cancers

Indianapolis, Indiana
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

250 Participants Needed

Fenretinide for T-Cell Lymphoma

Ann Arbor, Michigan
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

46 Participants Needed

Why Other Patients Applied

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

IPH4102 for Cutaneous T-Cell Lymphoma

Pittsburgh, Pennsylvania
This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

170 Participants Needed

Mogamulizumab for Cutaneous T-Cell Lymphoma

Pittsburgh, Pennsylvania
This trial is testing a medication called mogamulizumab in adults with certain types of skin cancer that have come back or not responded to other treatments. The medication helps the immune system find and destroy cancer cells. Mogamulizumab is approved for treating various types of skin cancer.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

34 Participants Needed

SIM1811-03 for Cutaneous T-Cell Lymphoma

Detroit, Michigan
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SIM1811-03 in adult patients with advanced solid tumors and cutaneous T-cell lymphoma. SIM1811-03 is a first-in-class IgG1-based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting

100 Participants Needed

Pembrolizumab + Mogamulizumab for Cutaneous T-Cell Lymphoma

Ann Arbor, Michigan
This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each cycle. Mogamulizumab will be administered on Day 1, 8, 15, and 22 of Cycle 1. For Cycle 2 and subsequent cycles, mogamulizumab will be administered on Day 1, 15 and 29 of each cycle. Subjects will undergo a response assessment prior to Cycle 3 and every 2 cycles thereafter. Subjects will continue study treatment until documented progression, unacceptable toxicity, or any other condition for discontinuation is met in protocol. A maximum of 2 years of study treatment may be administered. If a subject achieves a complete response (CR) per mSWAT criteria after 3 months of study treatment (2 cycles), they will continue study therapy for an additional 6 months (4 cycles). If a confirmed and persistent CR is met, they may discontinue study treatment and enter an observation period in protocol. Repeat disease evaluation is required prior to study therapy discontinuation. Subjects who progress during the observation period may be eligible for up to an additional 9 cycles (1 year) of pembrolizumab and mogamulizumab.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

23 Participants Needed

HyBryte Cream for Cutaneous T-Cell Lymphoma

Pittsburgh, Pennsylvania
To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

80 Participants Needed

Belinostat/Pralatrexate + CHOP for T-Cell Lymphoma

Louisville, Kentucky
This trial is testing two new drugs, Belinostat and Pralatrexate, combined with standard chemotherapy in patients with newly diagnosed PTCL. The goal is to find the safest and most effective dose. The new drugs work by either blocking cancer cell growth or tricking cancer cells into absorbing a harmful substance. Pralatrexate is a specially designed drug with greater preclinical antitumor activity than methotrexate.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

504 Participants Needed

PRT2527 + Zanubrutinib for Blood Cancers

Charlottesville, Virginia
This trial is testing a new drug called PRT2527, which blocks a protein that helps cancer cells grow, in patients with certain blood cancers that have come back or did not respond to other treatments. It also tests PRT2527 in combination with another drug, zanubrutinib, which blocks a different protein involved in cancer growth. The goal is to find a safe and effective dose for these drugs.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

86 Participants Needed

Azacytidine + Romidepsin for Peripheral T-Cell Lymphoma

Charlottesville, Virginia
This trial is testing if a combination of two drugs, romidepsin and azacytidine, is safe and effective for patients with aggressive Peripheral T-Cell Lymphoma that hasn't responded to other treatments. The goal is to see if this combination works better than using just one drug alone. Romidepsin is approved for certain types of T-cell lymphoma and has shown positive results in various T-cell cancers.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

50 Participants Needed

Valemetostat for T-Cell Lymphoma

Chicago, Illinois
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

155 Participants Needed

SGN-35T for Lymphoma

Chicago, Illinois
This trial is testing a new drug in adults with certain types of lymphoma that haven't responded to other treatments. The drug works by targeting a protein on cancer cells and delivering a substance that kills them. This drug has shown high selectivity against specific cancer cells and has been approved for treating lymphoma patients.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

150 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Peripheral T-Cell Lymphoma clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Peripheral T-Cell Lymphoma clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Peripheral T-Cell Lymphoma trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Peripheral T-Cell Lymphoma is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Peripheral T-Cell Lymphoma medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Peripheral T-Cell Lymphoma clinical trials?

Most recently, we added HyBryte Cream for Cutaneous T-Cell Lymphoma, APR-TD011 Spray for Cutaneous T-Cell Lymphoma and Enasidenib for T-Cell Lymphoma to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top T-Cell Lymphoma Clinical Trials

Top Cutaneous T-Cell Lymphoma Clinical Trials

Top Mantle Cell Lymphoma Clinical Trials

Top Diffuse Large B-Cell Lymphoma Clinical Trials

Top Peripheral Neuropathy Clinical Trials

Top Peripheral Arterial Disease Clinical Trials

Top Lymphoma Clinical Trials

Top Follicular Lymphoma Clinical Trials

Top Hodgkin Lymphoma Clinical Trials

Top Hodgkin's Lymphoma Clinical Trials

Top Marginal Zone Lymphoma Clinical Trials

Top Non-Hodgkin's Lymphoma Clinical Trials

By Trial

Valemetostat for T-Cell Lymphoma

Pembrolizumab + Romidepsin for Lymphoma

Chemotherapy + Stem Cell Transplant + Romidepsin for T-Cell Lymphoma

Bexarotene + Radiotherapy for Cutaneous T-Cell Lymphoma

CRG-022 for Large B-Cell Lymphoma

CAR-T Cell Therapy for Lymphoma and Leukemia

NKTR-255 + CAR-T Therapy for Large B-cell Lymphoma

CPI-818 for T-Cell Lymphoma

Mogamulizumab for Preventing Adult T-Cell Leukemia/Lymphoma

Loncastuximab + Rituximab for Large B-Cell Lymphoma

Iomab-B + CAR-T Cell Therapy for Non-Hodgkin's Lymphoma

CRISPR CAR-T Cell Therapy for B-Cell Lymphoma

Related Searches

Top Ulcerative-colitis Clinical Trials

TTFields for Lung Cancer

Tiragolumab + Atezolizumab for Lung Cancer

Bosutinib for Chronic Myeloid Leukemia

Imaging and Abemaciclib for Breast Cancer

Robotic Ankle Assistance + Audiovisual Biofeedback for Cerebral Palsy

Blue-Light Therapy + Sonidegib for Basal Cell Carcinoma

Reducing Vaccine Hesitancy for COVID-19

Proton Therapy vs Photon Radiation for Esophageal Cancer

Epilepsy Visit Planner for Epilepsy

Aerosol Glycerine System for Detecting Lung Air Leaks

Empagliflozin for Type 1 Diabetes

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial